search
Back to results

Physiological vs Right Ventricular Pacing in Patients With Normal Ventricular Function Post-TAVI (PHYS-TAVI)

Primary Purpose

Transcatheter Aortic Valve Implantation, Physiological Pacing, Right Ventricular Pacing

Status
Active
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Physiological pacing
Right ventricular pacing
Sponsored by
Josep Lluis Mont Girbau
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Transcatheter Aortic Valve Implantation focused on measuring TAVI, Physiological Pacing, AV Block

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Successful implantation of TAVI according to VARC-2 criteria.
  • Indication of cardiac pacing due to AV block according to ESC Guidelines.
  • LVEF> 50%.
  • The patient must indicate their acceptance to participate in the study by signing an informed consent document.

Exclusion Criteria:

  • Ventricular dysfunction: LVEF <50%.
  • Transapical TAVI.
  • Participating currently in a clinical investigation that includes an active treatment.
  • Patients with left bundle branch block but without indication of pacing (AV block).
  • Life expectancy <12 months.

Sites / Locations

  • Hospital Clinic de Barcelona

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Physiological pacing

Right ventricular pacing

Arm Description

Lead placed in the His-Purkinje system (his or branch) in order to achieve QRS shortening and physiologic pacing. A backup lead will be implanted in the right ventricle. If hisian pacing is not achieved (QRS is not shortened > 20% or QRS is not <130ms), the left bundle branch will be paced according to the criteria established in the literature (right branch block and intrinsic deflection <85ms). Crossover from physiological pacing to right ventricular pacing will be allowed in the following situations: failed physiological pacing lead implantation; high thresholds (>3.5V / 1ms); no shortening of QRS (shortening <20%) or failure to meet non-selective HBP criteria or left bundle branch pacing criteria.

Lead placed in the right ventricle (conventional pacing).

Outcomes

Primary Outcome Measures

Clinical combined endpoint: survival; and improvement > 1 point in NYHA class or > 25% increase in the distance covered in the 6-minute walking test.
Determine the percentage of patients who improve at 12 months on a clinical combined endpoint: survival; and improvement > 1 point in NYHA class or > 25% increase in the distance covered in the 6-minute walking test.

Secondary Outcome Measures

Change in left ventricular ejection fraction.
Left ventricular ejection fraction (LVEF %) measured with Simpson method with echocardiography (Delta left ventricular ejection fraction: 12 months LVEF - baseline LVEF).
Correction of echocardiographic asynchrony: septal flash expressed in mm.
Correction of septal flash determined with echocardiography (M mode).
Distance covered in the 6-minute walking test.
Distance in meters walked in 6 minutes.
Change in NYHA functional class.
NYHA functional class I, II, III, IV.
Change in degree of mitral regurgitation.
Mitral regurgitation measured with echocardiography.
Change in NTproBNP.
NTproBNP blood levels.
Hospitalization due to heart failure.
Hospitalization: patient hospitalization (yes/no).
QRS duration
QRS duration (milliseconds) measured with a 12-lead ECG (in the electrophysiology lab polygraph)
Score on quality of life/symptoms Questionnaire (KCCQ-12 Kansas City Cardiomyopathy Questionnaire )
Score in KCCQ-12: 23 items; scores 1 - 100 (higher=better).
Correction of global longitudinal strain
Global longitudinal strain assessed with two-dimensional speckle-tracking echocardiography

Full Information

First Posted
July 14, 2020
Last Updated
August 16, 2023
Sponsor
Josep Lluis Mont Girbau
search

1. Study Identification

Unique Protocol Identification Number
NCT04482816
Brief Title
Physiological vs Right Ventricular Pacing in Patients With Normal Ventricular Function Post-TAVI
Acronym
PHYS-TAVI
Official Title
Randomized Study of Physiological vs Right Ventricular Pacing in Patients With Normal Ventricular Function Post-TAVI (PHYS-TAVI Trial)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
September 14, 2020 (Actual)
Primary Completion Date
June 30, 2023 (Actual)
Study Completion Date
October 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Josep Lluis Mont Girbau

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Single-center randomized trial in patients with pacing indication (AV block) after TAVI (transfemoral aortic valve implantation) and LVEF> 50%, that aims to study the percentage of patients who improve at 12 months in a combined clinical endpoint.
Detailed Description
There is currently no evidence of the best mode of definitive pacing after TAVI in patients with preserved systolic ventricular function and AV block. Through this study, investigators intend to elucidate the best post TAVI pacing strategy, comparing the effect of right apical pacing vs. physiological pacing on the evolution of both echocardiographic and clinical parameters. Investigators will include 24 patients without ventricular dysfunction (LVEF> 50%) and with AV block pacing indication after TAVI. Patients will be randomized to 2 types of pacing (parallel randomized trial): physiological or right ventricular pacing (conventional). PHYS-TAVI trial will analyze the following parameters in the 2 groups: survival; NYHA class; distance in the 6-minute walking test; hospital admissions; left ventricular function; echocardiographic asynchrony (strain and flash septal); NTproBNP; and quality of life/symptoms with the Kansas City Cardiomyopathy Questionnaire test (KCCQ-12) Clinical, and echocardiographic follow-up will be performed for 1 year.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Transcatheter Aortic Valve Implantation, Physiological Pacing, Right Ventricular Pacing, AV Block
Keywords
TAVI, Physiological Pacing, AV Block

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Masking Description
The patient will be explained to be randomized to either of the two branches. The type of therapy applied will not be communicated to the patient. The follow-up will be the same in the two branches. During the visits, it will not be said which therapy has been applied. The echocardiographer and the follow-up by the Hemodynamic Team will be blind.
Allocation
Randomized
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Physiological pacing
Arm Type
Experimental
Arm Description
Lead placed in the His-Purkinje system (his or branch) in order to achieve QRS shortening and physiologic pacing. A backup lead will be implanted in the right ventricle. If hisian pacing is not achieved (QRS is not shortened > 20% or QRS is not <130ms), the left bundle branch will be paced according to the criteria established in the literature (right branch block and intrinsic deflection <85ms). Crossover from physiological pacing to right ventricular pacing will be allowed in the following situations: failed physiological pacing lead implantation; high thresholds (>3.5V / 1ms); no shortening of QRS (shortening <20%) or failure to meet non-selective HBP criteria or left bundle branch pacing criteria.
Arm Title
Right ventricular pacing
Arm Type
Active Comparator
Arm Description
Lead placed in the right ventricle (conventional pacing).
Intervention Type
Device
Intervention Name(s)
Physiological pacing
Intervention Description
Pacing of the his bundle or the left bundle branch
Intervention Type
Device
Intervention Name(s)
Right ventricular pacing
Intervention Description
Conventional pacing; right ventricular pacing
Primary Outcome Measure Information:
Title
Clinical combined endpoint: survival; and improvement > 1 point in NYHA class or > 25% increase in the distance covered in the 6-minute walking test.
Description
Determine the percentage of patients who improve at 12 months on a clinical combined endpoint: survival; and improvement > 1 point in NYHA class or > 25% increase in the distance covered in the 6-minute walking test.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Change in left ventricular ejection fraction.
Description
Left ventricular ejection fraction (LVEF %) measured with Simpson method with echocardiography (Delta left ventricular ejection fraction: 12 months LVEF - baseline LVEF).
Time Frame
12 months
Title
Correction of echocardiographic asynchrony: septal flash expressed in mm.
Description
Correction of septal flash determined with echocardiography (M mode).
Time Frame
30 days; 12 months
Title
Distance covered in the 6-minute walking test.
Description
Distance in meters walked in 6 minutes.
Time Frame
30 days; 12 months
Title
Change in NYHA functional class.
Description
NYHA functional class I, II, III, IV.
Time Frame
30 days; 12 months
Title
Change in degree of mitral regurgitation.
Description
Mitral regurgitation measured with echocardiography.
Time Frame
12 months
Title
Change in NTproBNP.
Description
NTproBNP blood levels.
Time Frame
30 days; 12 months
Title
Hospitalization due to heart failure.
Description
Hospitalization: patient hospitalization (yes/no).
Time Frame
12 months
Title
QRS duration
Description
QRS duration (milliseconds) measured with a 12-lead ECG (in the electrophysiology lab polygraph)
Time Frame
Implant; 12 months
Title
Score on quality of life/symptoms Questionnaire (KCCQ-12 Kansas City Cardiomyopathy Questionnaire )
Description
Score in KCCQ-12: 23 items; scores 1 - 100 (higher=better).
Time Frame
30 days; 12 months
Title
Correction of global longitudinal strain
Description
Global longitudinal strain assessed with two-dimensional speckle-tracking echocardiography
Time Frame
30 days; 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Successful implantation of TAVI according to VARC-2 criteria. Indication of cardiac pacing due to AV block according to ESC Guidelines. LVEF> 50%. The patient must indicate their acceptance to participate in the study by signing an informed consent document. Exclusion Criteria: Ventricular dysfunction: LVEF <50%. Transapical TAVI. Participating currently in a clinical investigation that includes an active treatment. Patients with left bundle branch block but without indication of pacing (AV block). Life expectancy <12 months.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
José M Tolosana, MD, PhD
Organizational Affiliation
Institut Clínic Cardiovascular (ICCV), Hospital Clínic Barcelona.
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Margarida Pujol Lopez, MD
Organizational Affiliation
Institut Clínic Cardiovascular (ICCV), Hospital Clínic Barcelona.
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Lluís Mont, MD, PhD
Organizational Affiliation
Institut Clínic Cardiovascular (ICCV), Hospital Clínic Barcelona.
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Eduard Guasch, MD, PhD
Organizational Affiliation
Institut Clínic Cardiovascular (ICCV), Hospital Clínic Barcelona.
Official's Role
Study Chair
Facility Information:
Facility Name
Hospital Clinic de Barcelona
City
Barcelona
Country
Spain

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Physiological vs Right Ventricular Pacing in Patients With Normal Ventricular Function Post-TAVI

We'll reach out to this number within 24 hrs